Astrazeneca hopes that its new COPD triplet can gain share from Glaxosmithkline’s rival, but it is not planning a price war.
With the company’s Molgradex failing to beat standard of care in a rare lung disorder, the premise behind this project looks questionable.
Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.
Astrazeneca has made another push into artificial intelligence, but admits that it will be some time before it knows whether the technology has helped its drug discovery…
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to.
Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Duchenne muscular dystrophy attracts a new entrant in pamrevlumab, while Alnylam awaits more pivotal data with givosiran.
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.